Clinical outcomes among hospital patients with Middle East respiratory syndrome coronavirus (MERS-CoV) infection

Clinical outcomes among hospital patients with Middle East respiratory syndrome coronavirus (MERS-CoV) infection

Abdulrahman Mohammed G. Habib, Mohamed Abd Elghafour Ali, Baha R. Zouaoui, Mustafa Ahmed H. Taha, Bassem Sahsah Mohammed, Nazmus Saquib

Abstract Background Mortality is high among patients with Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection. We aimed to determine hospital mortality and the factors associated with it in a cohort of MERS-CoV patients. Methods We reviewed hospital records of confirmed cases (detection of virus by polymerase chain reaction from respiratory tract samples) of MERS-CoV patients (n = 63) admitted to Buraidah Central Hospital in Al-Qassim, Saudi Arabia between 2014 and 2017. We abstracted data on demography, vital signs, associated conditions presented on admission, pre-existing chronic diseases, treatment, and vital status. Bi-variate comparisons and multiple logistic regressions were the choice of data analyses. Results The mean age was 60 years (SD = 18.2); most patients were male (74.6%) and Saudi citizens (81%). All but two patients were treated with Ribavirin plus Interferon. Hospital mortality was 25.4%. Patients who were admitted with septic shock and/or organ failure were significantly more likely to die than patients who were admitted with pneumonia and/or acute respiratory distress syndrome (OR = 47.9, 95% CI = 3.9, 585.5, p-value 0.002). Age, sex, and presence of chronic conditions were not significantly associated with mortality. Conclusion Hospital mortality was 25%; septic shock/organ failure at admittance was a significant predictor of mortality.

2019

ribavirin, interferon alpha, MERS-CoV, Mortality

DOI: 10.1186/s12879-019-4555-5

BMC Infectious Diseases

BMC

Infectious and parasitic diseases

EN